DBV Technologies shares rebound 2.5% but remain down 33.5% over 3 months
The Châtillon biotech resists the turbulent macro environment on this Wednesday, driven by a rebound that erases some of its recent selling pressure. As the market holds its breath ahead of the Fed's rate decision, DBV Technologies stands out in an SBF 120 that progresses modestly during the session.
A rebound that compensates for only a fraction of a quarterly decline exceeding 33%
The stock is trading at €2.12 in mid-morning, up 2.51% from the previous close of €2.07. This movement places DBV among the strongest gains in the SBF 120, in a broad index that gains less than 0.2% during the session. Nevertheless, the rebound remains modest in light of the scale of the decline accumulated in recent weeks: DBV Technologies still shows a loss of nearly 9% over the week and more than 10% over the month.
Over three months, the decline reaches 33.44%, so today's gain erases only an infinitesimal part of it. The underlying trend therefore remains clearly bearish, with a stock that had tested its support in early September before breaking through this zone in the following days. The only notable exception in this picture: over one year, the stock maintains a gain of 28.3%, reflecting the volatility characteristic of this type of biopharmaceutical security in regulatory phase.
Technical configuration below its moving averages and short positions to monitor
The price at €2.12 remains significantly below its three moving averages: the 20-MA at €2.37 (difference of 10.46%), the 50-MA at €2.46 (difference of 13.74%) and the 200-MA at €3.13 (difference of 32.20%). This arrangement of moving averages reflects degraded momentum on all time scales. The RSI at 31 approaches the oversold zone without having crossed it yet, indicating gradual exhaustion of selling pressure without a confirmed reversal signal. The stock is trading between its support at €2.07 (tested again this Tuesday, which corresponds to the previous day's closing price) and a resistance at €2.57. A break through this resistance would require an additional gain of more than 20% from the current price, which appears ambitious in the present configuration.
Added to this is institutional downward pressure that is measured but increasing: according to declarations consulted, three funds collectively hold 3.70% of capital sold short, up nearly one percentage point over thirty days (versus 2.71% a month ago). This increase in short positions reflects growing interest from institutional players in a bearish exposure to the stock, without it being possible to determine the precise motivation. Furthermore, when publishing first-half 2026 results (July 16, 2026), DBV indicated that its cash reserves covered the company's financing through the third quarter of 2027, with submission of a BLA file to the FDA anticipated in the third quarter of 2026, a milestone whose outcome will determine a large part of the stock's trajectory. The analysts' opinions remain a key follow-up point for calibrating the evolution of expectations around this regulatory matter.
